proposition is "Preventing the Preventable" — that is, improving patient outcomes and
reducing healthcare costs by preventing unnecessary cardiac procedures and
procedure-related side effects, as well as predicting — and hopefully thereby preventing — one year adverse cardiac events,
including myocardial infarct (MI), heart failure, and cardiovascular death.
In the U.S.
alone, more than 7 million patients annually enter the Emergency Room
(ER) with complaints about chest pain. It is the second most common reason
for ER visits in the US.
ER physicians and
cardiologists have tests (ECGs and troponins) to diagnose patients who
have already had a heart attack. However,
frequently these tests are inconclusive. Additionally, many
patients experience chest pain due to non-cardiac reasons, including heartburn,
esophageal reflux, and other non-life threatening conditions. Unfortunately,
these patients may end up in a diagnostic "gray zone" and a
significant number receive expensive and dangerous procedures they do
not actually need, including cardiac catheterization ("caths")
and coronary CT scans.
These are the patients
who benefit the most from Prevencio's multi-protein HART™ CAD test for obstructive coronary artery disease diagnosis.
cardiac caths and other cardiac testing procedures may save more than $39,000
per patient. With more than one million in-patient cardiac caths in the US
every year, we spend more than $39 billion annually. Eliminating a small
percentage of the needless cardiac caths could amount to billions of dollars in
savings. Additionally, unneeded cardiac procedures, including cardiac caths,
have patient risks, including contrasting dye toxicity, radiation exposure, and
death. These types of procedures account for 1.5% of all cancer in the U.S.
In addition to the HART™
CAD test for assessing obstructive coronary artery disease (CAD), Prevencio is
developing multi-protein tests for predicting — and hopefully thereby preventing — one year adverse cardiac events, including
myocardial infarct, heart failure, and death.
The HART™ tests will be
able to reduce patient risks and reduce costs for cardiac patients and
healthcare systems around the world.
Prevencio® is the registered trademark of Prevencio, Inc., a Delaware Corporation. Copyright (2016). All rights reserved. Prevencio's products described here are not for sale and have not been cleared by the FDA for commercial sale.